Hinokitiol Preventing Porphyromonas gingivalis from Forming Biofilm and Producing Gingipains via Quorum Sensing Inhibition | Chapter 2 | Current Progress in Medicine and Medical Research Vol. 6

 The aim concerning this study is to verify that hinokitiol restrain biofilm formation and gingipain result by inhibiting quorum noticing in Porphyromonas gingivalis.  Periodontal disease is a incessant inflammatory condition caused apiece colonization of P. gingivalis, which form biofilms and produce resentment factors in the way that gingipains. It is known that the formation of biofilms and the result of gingipains in P. gingivalis are regulated by majority sensing via autoinducer-2 (AI-2). In this study, we speculated that hinokitiol, a natural purifier, can inhibit quorum thinking in P. gingivalis at sublethal concentration, thereby restraining biofilm formation and gingipain result, leading to therapeutic belongings against periodontal disease. AI-2 bioassay accompanying Vibrio harveyi revealed that 20–300 µM hinokitiol inhibited V. harveyi moonshine caused by AI-2. Furthermore, 100 µM hinokitiol inhibited the AI-2 action in a culture light in weight of P. gingivalis. Therefore, we evaluated whether hinokitiol at sublethal concentrations restrained biofilm formation and gingipain result. A 96-well plate biofilm assay showed that 70–100 µM hinokitiol suppressed biofilm biomass. Moreover, the abolition of biofilm formation shortened resistance of P. gingivalis to hinokitiol. Western blotting analysis disclosed that the expressions of membrane-limited Arg-gingipain and secreted Arg-gingipain and Lys-gingipain were restrained by 30 µM of hinokitiol. These findings suggested that hinokitiol restrain biofilm formation and gingipain result by inhibiting P. gingivalis quorum anticipating via AI-2.

Author(s) Details:

Shoko Hamada,
Department of Core Technology Research, Central R&D Laboratory, KOBAYASHI Pharmaceutical Co., Ltd., 1-30-3, Toyokawa, Ibaraki, Osaka, 567-0057, Japan.

Mitsuhiro Gomi,
Department of Core Technology Research, Central R&D Laboratory, KOBAYASHI Pharmaceutical Co., Ltd., 1-30-3, Toyokawa, Ibaraki, Osaka, 567-0057, Japan.

Akihiro Yoshida,
Department of Oral Microbiology, Matsumoto Dental University School of Dentistry, 1780, Gobara Hiro-oka, Shiojiri, Nagano, 399-0781, Japan.

Please see the link here: https://stm.bookpi.org/CPMMR-V6/article/view/11473